Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Long-Term Deferred Tax (2019 - 2020)

Celldex Therapeutics has reported Long-Term Deferred Tax over the past 2 years, most recently at $63.2 million for Q4 2020.

  • Quarterly results put Long-Term Deferred Tax at $63.2 million for Q4 2020, down 9.75% from a year ago — trailing twelve months through Dec 2020 was $63.2 million (down 9.75% YoY), and the annual figure for FY2020 was $63.2 million, down 9.75%.
  • Long-Term Deferred Tax for Q4 2020 was $63.2 million at Celldex Therapeutics, down from $70.0 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for CLDX hit a ceiling of $70.0 million in Q4 2019 and a floor of $63.2 million in Q4 2020.